Apremilast improves the signs and symptoms of psoriatic arthritis in about 60% of patients at 1 year, according to long-term data from the PALACE 1 trial.
Dr. Arthur Kavanaugh discusses the results below.
For complete coverage of the EULAR Congress 2013, visit Rheumatology News at http://www.rheumatologynews.com